Cite
HARVARD Citation
Zenger, C. et al. (n.d.). S961 Risk of New or Recurrent Cancer After Vedolizumab or Ustekinumab Exposure in Patients With Inflammatory Bowel Disease and Previous Cancer. American journal of gastroenterology. p. S460. [Online].